Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them

Yingxian Xiao, Hong Fan, John L. Musachio, Zhi Liang Wei, Sheela K. Chellappan, Alan P. Kozikowski, Kenneth J. Kellar

Research output: Contribution to journalArticle

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found throughout the central and peripheral nervous systems. They are crucial to normal physiology and have been clearly implicated in nicotine addiction. In addition, they are possible therapeutic targets in a wide range of pathological conditions, including cognitive disorders, Parkinson's disease, and neuropathic pain. Nicotinic ligands are usually classified as agonists (or partial agonists), competitive antagonists, or noncompetitive antagonists. Sazetidine-A is a new nicotinic ligand that shows a different pharmacological profile from any of these known classes of ligands. Sazetidine-A competes with very high binding affinity (Ki ≈ 0.5 nM) and selectivity for the α4β2 nAChR subtype (Ki ratio α3β4/ α4β2 ∼ 24,000). Despite its high affinity, sazetidine-A neither activates nAChR channel function nor prevents channel activation when it is applied simultaneously with nicotine. However, when it is pre-incubated for 10 min with the receptors, it potently blocks nicotine-stimulated α4β2 nAChR function (IC50 ≈ 30 nM). The action of sazetidine-A may be explained by its very low affinity for the resting conformation of the α4β2 nAChRs, and its very high affinity for the desensitized state of the receptor. We propose that sazetidine-A is a "silent desensitizer" of nAChRs, meaning that it desensitizes the receptor without first activating it. Furthermore, comparison of the effects of sazetidine-A and nicotine at α4β2 nAChRs suggests that the predominant effects of nicotine and other nicotinic agonists are related to desensitization of the receptors and that sazetidine-A potently mimics these effects.

Original languageEnglish (US)
Pages (from-to)1454-1460
Number of pages7
JournalMolecular Pharmacology
Volume70
Issue number4
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Nicotinic Receptors
Nicotine
Ligands
Nicotinic Agonists
Ligand-Gated Ion Channels
Peripheral Nervous System
Neuralgia
sazetidine-A
Inhibitory Concentration 50
Parkinson Disease
Central Nervous System
Pharmacology

ASJC Scopus subject areas

  • Pharmacology

Cite this

Xiao, Y., Fan, H., Musachio, J. L., Wei, Z. L., Chellappan, S. K., Kozikowski, A. P., & Kellar, K. J. (2006). Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them. Molecular Pharmacology, 70(4), 1454-1460. https://doi.org/10.1124/mol.106.027318

Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them. / Xiao, Yingxian; Fan, Hong; Musachio, John L.; Wei, Zhi Liang; Chellappan, Sheela K.; Kozikowski, Alan P.; Kellar, Kenneth J.

In: Molecular Pharmacology, Vol. 70, No. 4, 2006, p. 1454-1460.

Research output: Contribution to journalArticle

Xiao, Y, Fan, H, Musachio, JL, Wei, ZL, Chellappan, SK, Kozikowski, AP & Kellar, KJ 2006, 'Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them', Molecular Pharmacology, vol. 70, no. 4, pp. 1454-1460. https://doi.org/10.1124/mol.106.027318
Xiao, Yingxian ; Fan, Hong ; Musachio, John L. ; Wei, Zhi Liang ; Chellappan, Sheela K. ; Kozikowski, Alan P. ; Kellar, Kenneth J. / Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them. In: Molecular Pharmacology. 2006 ; Vol. 70, No. 4. pp. 1454-1460.
@article{512e224eaccd4509b8eb8ff59f2bfb5c,
title = "Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them",
abstract = "Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found throughout the central and peripheral nervous systems. They are crucial to normal physiology and have been clearly implicated in nicotine addiction. In addition, they are possible therapeutic targets in a wide range of pathological conditions, including cognitive disorders, Parkinson's disease, and neuropathic pain. Nicotinic ligands are usually classified as agonists (or partial agonists), competitive antagonists, or noncompetitive antagonists. Sazetidine-A is a new nicotinic ligand that shows a different pharmacological profile from any of these known classes of ligands. Sazetidine-A competes with very high binding affinity (Ki ≈ 0.5 nM) and selectivity for the α4β2 nAChR subtype (Ki ratio α3β4/ α4β2 ∼ 24,000). Despite its high affinity, sazetidine-A neither activates nAChR channel function nor prevents channel activation when it is applied simultaneously with nicotine. However, when it is pre-incubated for 10 min with the receptors, it potently blocks nicotine-stimulated α4β2 nAChR function (IC50 ≈ 30 nM). The action of sazetidine-A may be explained by its very low affinity for the resting conformation of the α4β2 nAChRs, and its very high affinity for the desensitized state of the receptor. We propose that sazetidine-A is a {"}silent desensitizer{"} of nAChRs, meaning that it desensitizes the receptor without first activating it. Furthermore, comparison of the effects of sazetidine-A and nicotine at α4β2 nAChRs suggests that the predominant effects of nicotine and other nicotinic agonists are related to desensitization of the receptors and that sazetidine-A potently mimics these effects.",
author = "Yingxian Xiao and Hong Fan and Musachio, {John L.} and Wei, {Zhi Liang} and Chellappan, {Sheela K.} and Kozikowski, {Alan P.} and Kellar, {Kenneth J.}",
year = "2006",
doi = "10.1124/mol.106.027318",
language = "English (US)",
volume = "70",
pages = "1454--1460",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Sazetidine-A, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them

AU - Xiao, Yingxian

AU - Fan, Hong

AU - Musachio, John L.

AU - Wei, Zhi Liang

AU - Chellappan, Sheela K.

AU - Kozikowski, Alan P.

AU - Kellar, Kenneth J.

PY - 2006

Y1 - 2006

N2 - Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found throughout the central and peripheral nervous systems. They are crucial to normal physiology and have been clearly implicated in nicotine addiction. In addition, they are possible therapeutic targets in a wide range of pathological conditions, including cognitive disorders, Parkinson's disease, and neuropathic pain. Nicotinic ligands are usually classified as agonists (or partial agonists), competitive antagonists, or noncompetitive antagonists. Sazetidine-A is a new nicotinic ligand that shows a different pharmacological profile from any of these known classes of ligands. Sazetidine-A competes with very high binding affinity (Ki ≈ 0.5 nM) and selectivity for the α4β2 nAChR subtype (Ki ratio α3β4/ α4β2 ∼ 24,000). Despite its high affinity, sazetidine-A neither activates nAChR channel function nor prevents channel activation when it is applied simultaneously with nicotine. However, when it is pre-incubated for 10 min with the receptors, it potently blocks nicotine-stimulated α4β2 nAChR function (IC50 ≈ 30 nM). The action of sazetidine-A may be explained by its very low affinity for the resting conformation of the α4β2 nAChRs, and its very high affinity for the desensitized state of the receptor. We propose that sazetidine-A is a "silent desensitizer" of nAChRs, meaning that it desensitizes the receptor without first activating it. Furthermore, comparison of the effects of sazetidine-A and nicotine at α4β2 nAChRs suggests that the predominant effects of nicotine and other nicotinic agonists are related to desensitization of the receptors and that sazetidine-A potently mimics these effects.

AB - Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found throughout the central and peripheral nervous systems. They are crucial to normal physiology and have been clearly implicated in nicotine addiction. In addition, they are possible therapeutic targets in a wide range of pathological conditions, including cognitive disorders, Parkinson's disease, and neuropathic pain. Nicotinic ligands are usually classified as agonists (or partial agonists), competitive antagonists, or noncompetitive antagonists. Sazetidine-A is a new nicotinic ligand that shows a different pharmacological profile from any of these known classes of ligands. Sazetidine-A competes with very high binding affinity (Ki ≈ 0.5 nM) and selectivity for the α4β2 nAChR subtype (Ki ratio α3β4/ α4β2 ∼ 24,000). Despite its high affinity, sazetidine-A neither activates nAChR channel function nor prevents channel activation when it is applied simultaneously with nicotine. However, when it is pre-incubated for 10 min with the receptors, it potently blocks nicotine-stimulated α4β2 nAChR function (IC50 ≈ 30 nM). The action of sazetidine-A may be explained by its very low affinity for the resting conformation of the α4β2 nAChRs, and its very high affinity for the desensitized state of the receptor. We propose that sazetidine-A is a "silent desensitizer" of nAChRs, meaning that it desensitizes the receptor without first activating it. Furthermore, comparison of the effects of sazetidine-A and nicotine at α4β2 nAChRs suggests that the predominant effects of nicotine and other nicotinic agonists are related to desensitization of the receptors and that sazetidine-A potently mimics these effects.

UR - http://www.scopus.com/inward/record.url?scp=33748927988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748927988&partnerID=8YFLogxK

U2 - 10.1124/mol.106.027318

DO - 10.1124/mol.106.027318

M3 - Article

C2 - 16857741

AN - SCOPUS:33748927988

VL - 70

SP - 1454

EP - 1460

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -